ProMIS Neurosciences announced the presentation of its precision design approach and preclinical data for its lead product candidates, at the Alzheimer’s Association International Conference.

ProMIS Neurosciences (TSX:PMN) announced the presentation of its precision design approach and preclinical data for its lead product candidates, at the Alzheimer’s Association International Conference.
As quoted in the press release:

Commenting on the ProMIS podium presentation at AAIC, Eugene Williams, ProMIS Executive Chairman stated: “We continue to make significant progress with our Alzheimer’s program, selectively targeting toxic amyloid beta oligomers, widely recognized at the conference to be a root cause of Alzheimer’s. The unique characteristics of our lead products in development, PMN310 and PMN350, distinguishes them from other antibodies targeting amyloid beta currently undergoing clinical trials and are designed to address observed issues of safety and efficacy”.
Several presentations at the AAIC meeting by other specialist groups in the field also underlined the importance of selectively targeting and neutralizing toxic AbO for effective treatment of Alzheimer’s.

Click here to read the full press release.

Source: www.newswire.ca

candidates clinical trials preclinical data product candidates promis promis neurosciences trials Biotech Investing